Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

DelMar and Guangxi Wuzhou Pharmas Form Advisory Board for Cancer Drug

publication date: Sep 9, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
DelMar Pharma and Guangxi Wuzhou Pharma have formed a China clinical advisory board to oversee trials of their cancer treatment, which is known as VAL-083 or "DAG for Injection." The drug is already approved in China for leukemia and lung cancer. The two companies are working together to gain China approval for VAL-083 as a treatment for glioblastoma multiforme, the most aggressive form of brain cancer, and global approval for all indications. More details....

Stock Symbol: (OTCQB: DMPI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners